Hiring freeze

Quote
Re: MilkRe: Hiring freeze

Anonymous said:
We'll be a little late to the game. The glaucoma market is turning all generic.
Click to expand...

Name me a market that ISN'T going generic. There have been generic antibiotics, NSAIDs, steroids, statins, PPIs, etc, etc, etc and companies still have reps promoting the branded products.

There's a lot of innovation going on in the ophthalmology space (mostly with a lot of niche companies right now that Valeant will probably try to buy at garage sale prices eventually). Most of that innovation is happening in glaucoma and dry eye. Just because things go generic doesn't mean the opportunity is gone, otherwise you wouldn't see R&D happening in these areas.

Glaucoma will be a battle on share of voice like big pharma and B+L gonna need foot soldiers to pound the pavement. Whether you want to be here or not is a different story, but they will need reps to win share against Alcon, Allergan, and the other companies that ramp up their sales force right before FDA approval.
 






Re: MilkRe: Hiring freeze

Anonymous said:
Name me a market that ISN'T going generic. There have been generic antibiotics, NSAIDs, steroids, statins, PPIs, etc, etc, etc and companies still have reps promoting the branded products.

There's a lot of innovation going on in the ophthalmology space (mostly with a lot of niche companies right now that Valeant will probably try to buy at garage sale prices eventually). Most of that innovation is happening in glaucoma and dry eye. Just because things go generic doesn't mean the opportunity is gone, otherwise you wouldn't see R&D happening in these areas.

Glaucoma will be a battle on share of voice like big pharma and B+L gonna need foot soldiers to pound the pavement. Whether you want to be here or not is a different story, but they will need reps to win share against Alcon, Allergan, and the other companies that ramp up their sales force right before FDA approval.
Click to expand...

Oh really? This new drug is not unique nor will it produce a big enough difference in IOP reduction and control to warrant a sales force behind it. Allergen & Alcon are fighting to keep enough market share to justify JOBS.
 






I hope this restructuring doesn't stop at the salesforce. Maybe RL and TV will get their walking papers. Incompetent leaders. They've completely ruined morale in a very short time.
 






Q1 Scorecard payouts are embarrassing and insulting to the field. Hiring freeze + minimal payouts = significant turnover. This is probably part of the master reorg plan.
 












Re: MilkRe: Hiring freeze

Anonymous said:
Oh really? This new drug is not unique nor will it produce a big enough difference in IOP reduction and control to warrant a sales force behind it. Allergen & Alcon are fighting to keep enough market share to justify JOBS.
Click to expand...

Probably true that it's not unique, but when has that ever stopped leadership from believing that it is?

In my 20 years of pharma, I've never been with a company whose leadership doesn't think a new drug is gonna be a blockbuster and will be the greatest thing since sliced bread. This leadership is no different and because they believe the new glaucoma drug is going to take the ophthalmology world by storm, they will want to have as many boots on the ground as possible.
 


















Top Bottom
Back
Quote